{"id":"NCT00195702","sponsor":"Abbott","briefTitle":"Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Rheumatoid Arthritis Patients Currently Receiving Treatment With Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2000-02","primaryCompletion":"2002-09","completion":"2010-08","firstPosted":"2005-09-20","resultsPosted":"2010-03-01","lastUpdate":"2011-08-26"},"enrollment":619,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"DB adalimumab 20 mg ew","type":"EXPERIMENTAL"},{"label":"DB adalimumab 40 mg eow","type":"EXPERIMENTAL"},{"label":"DB placebo ew","type":"PLACEBO_COMPARATOR"},{"label":"DB adalimumab 20 mg ew/OL adalimumab 40 mg eow","type":"EXPERIMENTAL"},{"label":"DB adalimumab 40 mg eow/OL adalimumab 40 mg eow","type":"EXPERIMENTAL"},{"label":"DB placebo ew/OL adalimumab 40 mg eow","type":"EXPERIMENTAL"}],"summary":"The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension phase) in patients with persistently active rheumatoid arthritis who were receiving concurrent methotrexate therapy.","primaryOutcome":{"measure":"Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"DB Adalimumab 20 mg ew","deltaMin":129,"sd":null},{"arm":"DB Adalimumab 40 mg Eow","deltaMin":131,"sd":null},{"arm":"DB Placebo ew","deltaMin":59,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":87,"countries":["United States","Canada"]},"refs":{"pmids":["31707982","29018564","27338778","25139667","25073879","23818718","21285171"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":212},"commonTop":["Upper respiratory tract infection","Sinusitis","Injection site pain","Nasopharyngitis","Rheumatoid arthritis"]}}